Anger In Kenya Over Distribution Of Expired HIV Drugs

Anger In Kenya Over Distribution Of Expired HIV Drugs
Listen to article

The head of an organisation for people living with HIV in Kenya has accused the government of insensitivity and putting people’s lives at risk after it distributed HIV drugs that had been discontinued.

The head of the organization identified as Nelson Otuoma claimed that some patients had exhibited unexpected side effects after taking the drugs which he believes they shouldn’t have been allowed to take.

The 24,000 packs were part of old stock donated by the Global Fund and the President’s Emergency Plan for AIDS Relief (Pepfar).

They were distributed to 31 towns across the country amid a shortage of HIV drugs.

Read Also: 1.9 Million Nigerians Living With HIV/AIDs – Expert

The drugs are a combined dosage of Zidovudine, Lamivudine, and Nevirapine – which were discontinued in 2019.

Nevirapine is usually administered  as a single drug or as part of a three-drug fixed-dose combination.

Its common side effects include abdominal pain, rash, fatigue, headache, and muscle pain, which lasts for a month.

It has also been associated with liver damage in some people. Many countries are opting not to use it.

The World Health Organization (WHO) has said that Nevirapine-based treatment recorded an unacceptably high failure rate and had to be changed.

Mr. Otuoma said that the government had told activists they had destroyed the drugs that they then went on to distribute last week:

‘Why is the government playing with people’s lives? We have told them so many times that these drugs are not working because of the side effects that they are associated with,’ Mr. Otuoma said.

‘We are surprised that these drugs were still at the warehouse for months. They told us that they had already been destroyed,’ He added.

The BBC asked the health ministry for comment but they have declined to provide any.

 

AFRICA TODAY NEWS, NEW YORK

Share this post

Share on whatsapp
WhatsApp
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Related news

Scroll to Top